Evidence poor for link between biomarkers and risk of CV events for patients with kidney disease

Mar 15, 2011

Even though clinical practice guidelines for patients with chronic kidney disease recommend specific treatment target levels for serum phosphorus, parathyroid hormone, and calcium to reduce the risk of cardiovascular events, an analysis of data from previous studies did not find a strong association between these biomarkers and the risk of death and cardiovascular events, except for higher serum phosphorus levels, according to an article in the March 16 issue of JAMA.

"Nephrology guidelines recommend targets and treatment strategies to correct of phosphorus, calcium, and hormone because observational data suggest there is an association between these potential risk biomarkers and vascular disease and death. However, to date, randomized controlled trials have not shown that treating mineral levels with existing treatment options reduces cardiovascular events or mortality," according to background information in the article. The authors add that existing guidelines (based primarily on observational studies) may be inappropriately promoting treatment for abnormal mineral metabolism in individuals with .

Suetonia C. Palmer, M.B., Ch.B., Ph.D., of the University of Otago, Christchurch, New Zealand, and colleagues conducted a review and meta-analysis to evaluate the quality of evidence for the association between levels of serum phosphorus, , and calcium and risks of death, cardiovascular death, and nonfatal in individuals with chronic kidney disease. Through a search of databases, the researchers identified 47 studies (n = 327,644 patients) that met the inclusion criteria.

The analysis indicated that for every 1-mg/dL increase in serum phosphorus, the risk of death increased 18 percent. "There was no significant association between all-cause mortality and serum level of parathyroid hormone or serum level of calcium. Data for the association between serum level of phosphorus, parathyroid hormone, and calcium and cardiovascular death were each available in only 1 adequately adjusted cohort study," the authors write.

"… based on the available cohort data and the absence of randomized controlled trials, the evidentiary basis for current clinical guideline-recommended targets of serum phosphorus, parathyroid hormone, and calcium in chronic kidney disease is poor. Broad adoption of health care practices that have insufficient evidence for safety or efficacy (in this case targeting serum mineral levels in individuals with chronic kidney disease) may lead to considerable unintended harm," the authors write.

"Large placebo-controlled randomized trials of vitamin D compounds, phosphorus binders, and calcimimetic agents are now needed to evaluate whether treating mineral disorders improves health outcomes for individuals with chronic kidney disease."

Explore further: Cooling of dialysis fluids protects against brain damage

More information: JAMA. 2011;305[11]1119-1127.

add to favorites email to friend print save as pdf

Related Stories

Vitamin D linked to reduced mortality rate in CKD

May 07, 2008

For patients with moderate to severe chronic kidney disease (CKD), treatment with activated vitamin D may reduce the risk of death by approximately one-fourth, suggests a study in the August Journal of the American Society of ...

Kidney disease patients reap rewards of prevention

May 07, 2009

Making sure you see your doctor and have tests run on a regular basis can prevent serious complications of chronic kidney disease (CKD), according to a study appearing in an upcoming issue of the Journal of the American So ...

Recommended for you

Cooling of dialysis fluids protects against brain damage

9 hours ago

While dialysis can cause blood pressure changes that damage the brain, cooling dialysis fluids can protect against such effects. The findings come from a study appearing in an upcoming issue of the Journal of the American So ...

Two Ebola vaccines to be tested in Switzerland

10 hours ago

Clinical trials of two experimental vaccines against the deadly Ebola virus are due to begin soon in Switzerland, the country's Tropical and Public Health Institute said on Thursday.

Legionnaire's disease kills four in Spain

14 hours ago

Four people have died from an outbreak of the lung infection Legionnaire's disease in northeastern Spain, regional health authorities said Thursday.

User comments : 0